Commentary: The Multiple Sclerosis Controversy: Is It Escalation or Induction High Efficacy?
作者信息
Coyle Patricia K
机构信息
Department of Neurology, Stony Brook University Medical Center, Stony Brook, NY, 11794, USA.
出版信息
Neurotherapeutics. 2020 Jul;17(3):971-972. doi: 10.1007/s13311-020-00869-8.
Abstract
摘要
相似文献
1
Commentary: The Multiple Sclerosis Controversy: Is It Escalation or Induction High Efficacy?评论：多发性硬化症之争：是病情升级还是诱导高效能？
Neurotherapeutics. 2020 Jul;17(3):971-972. doi: 10.1007/s13311-020-00869-8.
2
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.在复发缓解型多发性硬化症患者中，从每周给药 4 周转换为每周给药 6 周与继续每周给药 4 周的比较（NOVA）：一项随机、对照、开放标签、3b 期试验。
Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25.
3
Commentary on "Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis".关于“一名多发性硬化症患者在使用那他珠单抗后发生进行性多灶性白质脑病并成功妊娠”的评论
Mult Scler. 2017 Mar;23(3):486-487. doi: 10.1177/1352458516675752. Epub 2016 Nov 12.
4
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.在复发缓解型多发性硬化症中，与那他珠单抗、芬戈莫德和干扰素β相比，阿仑单抗的治疗效果：一项队列研究。
Lancet Neurol. 2017 Apr;16(4):271-281. doi: 10.1016/S1474-4422(17)30007-8. Epub 2017 Feb 11.
5
Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy.在意大利，对复发缓解型多发性硬化症中升级使用那他珠单抗或免疫调节剂之间转换的成本效果分析。
BMC Health Serv Res. 2019 Jun 28;19(1):436. doi: 10.1186/s12913-019-4264-1.
6
White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.复发缓解型多发性硬化症患者接受那他珠单抗治疗第一年期间的白质扩散变化
AJNR Am J Neuroradiol. 2016 Jun;37(6):1030-7. doi: 10.3174/ajnr.A4690. Epub 2016 Mar 10.
7
Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary.三名多发性硬化症患者孕期那他珠单抗的血药浓度：临床述评
Mult Scler. 2022 Feb;28(2):326-327. doi: 10.1177/13524585211069922.
8
Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis.那他珠单抗：复发缓解型多发性硬化症患者的安全性和风险。
Eur J Hosp Pharm. 2021 Mar;28(2):112-114. doi: 10.1136/ejhpharm-2019-002048. Epub 2019 Oct 16.
9
Disease activity return after natalizumab cessation in multiple sclerosis.多发性硬化症患者停用那他珠单抗后疾病活动度复发。
Expert Rev Neurother. 2016 May;16(5):587-94. doi: 10.1586/14737175.2016.1168295. Epub 2016 Apr 6.
10
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.在英国，对比那珠单抗和芬戈莫德治疗快速进展性重度复发缓解型多发性硬化的疗效和成本效益。
J Med Econ. 2024 Jan-Dec;27(1):109-125. doi: 10.1080/13696998.2023.2293379. Epub 2023 Dec 26.
引用本文的文献
1
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.治疗初发缓解型多发性硬化症的高效疗法。
CNS Drugs. 2022 Dec;36(12):1285-1299. doi: 10.1007/s40263-022-00965-7. Epub 2022 Nov 9.
2
Escalation vs. Early Intense Therapy in Multiple Sclerosis.多发性硬化症中的强化治疗与早期强化治疗对比
J Pers Med. 2022 Jan 17;12(1):119. doi: 10.3390/jpm12010119.
本文引用的文献
1
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.多发性硬化症高疗效治疗时机：一项回顾性观察队列研究。
Lancet Neurol. 2020 Apr;19(4):307-316. doi: 10.1016/S1474-4422(20)30067-3. Epub 2020 Mar 18.
2
Immune reconstitution therapies: concepts for durable remission in multiple sclerosis.免疫重建疗法：多发性硬化症持久缓解的概念。
Nat Rev Neurol. 2020 Jan;16(1):56-62. doi: 10.1038/s41582-019-0268-z. Epub 2019 Oct 24.
3
Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.多发性硬化症患者强化治疗与早期强化疾病修正治疗的临床结局。
JAMA Neurol. 2019 May 1;76(5):536-541. doi: 10.1001/jamaneurol.2018.4905.
4
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.初始疾病修饰治疗与随后继发进展性多发性硬化转化的相关性。
JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588.
5
Multiple Sclerosis.多发性硬化症
N Engl J Med. 2018 Jan 11;378(2):169-180. doi: 10.1056/NEJMra1401483.
6
Optimizing treatment success in multiple sclerosis.优化多发性硬化症的治疗效果。
J Neurol. 2016 Jun;263(6):1053-65. doi: 10.1007/s00415-015-7986-y. Epub 2015 Dec 24.
Zotero 插件